TACT-D: Determining ctDNA Response in Patients With Metastatic Colorectal Cancer
By Kanwal Raghav, MBBS, MD - Last Updated: March 19, 2025Kanwal Raghav, MBBS, MD, discusses his recent study on ctDNA response in patients with metastatic colorectal cancer.
Advertisement
Dr. Raghav explains how using ctDNA changes as an early predictor of treatment response in metastatic colorectal cancer compares to traditional radiographic assessment.
Find more ASCO 2024 coverage here.
Advertisement
Related Posts
Dr. Christopher Lieu shares his top liver-directed therapies for metastatic colorectal cancer with liver involvement.
Dr. Christopher Lieu shares his list of top targeted therapies for metastatic colorectal cancer.
The DYNAMIC study began in 2015 to analyze the efficacy of ctDNA in guiding the use of adjuvant chemotherapy.
Dr. Alan Venook reflects on how his leadership roles have shaped his collaborative approach to cancer research and treatment.
Sotorasib plus panitumumab may prolong progression-free survival in patients with KRAS G12C mCRC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.